

Ohio Department of Medicaid (ODM)
Drug Utilization Review (DUR) Board
Quarterly Meeting
February 7, 2017

The quarterly meeting of the ODM DUR Board was called to order at 12:02 PM EST in room B406, 50 West Town Street, Columbus, Ohio. Lenard Presutti, DO, presided. The following Board members were present:

David Brookover, R.Ph.
Michael K. Farrell, M.D.
Robert B. Kubasak, R.Ph.
Lenard G. Presutti, D.O., Chair

Also present from ODM were Margaret Scott, RPh, DUR Administrator and Michael Howcroft, RPh. Pam Heaton, RPh, PhD, represented the University of Cincinnati. Benjamin Link, Pharm D, Jill Griffith, PharmD and Gail Master, RPh, from Change Healthcare were present. Approximately 6 observers were present, most representing pharmaceutical manufacturers.

Roll Call, Reading, Correction, and Approval of previous Minutes

The September 20, 2016 DUR Board Meeting minutes were approved (1st D. Brookover, 2nd R. Kubasak)

DUR Committee Report

M. Scott reviewed that during the January DUR Committee meeting, the risks of taking opioids concurrently with benzodiazepines and/or sedative hypnotics were discussed. The Board reviewed a draft DUR letter that would first, inform prescribers of member concurrent utilization and the dangers of prescribing these medications together, and secondly, remind them to check OARRS. By consensus, the Board recommended format changes to the letter and agreed to its content.

Health Plan Policy

M. Scott reviewed the budget proposal by the Ohio Governor for 2018-2019 as it related to Medicaid. Additional details would be made available following legislative review of the budget proposals. M. Scott also provided an update on the future role of the DUR program.

Unfinished Business

It was identified that the state staff member who was going to evaluate the role of the DUR program in other states was no longer with ODM and so this evaluation would be presented at a later date.

Elections

Elections for Chair and Vice Chair were held. R. Kubasak, RPh was elected Chair and M. Farrell, MD was elected Vice Chair.

Conflict of Interest Statement

The DUR Board members reviewed and signed the annual Conflict of Interest Statement.

Proposed Prospective DUR

B. Link presented information detailing utilization of opioids, benzodiazepines and hypnotic agents in the fee-for-service population. The information was presented so that the Board may evaluate the appropriateness of these combinations and consider potential future proDUR edits. The Board discussed the need to balance appropriate warnings to providers with the need to ensure access to care for members. It was recognized that pharmacy claims data are limited by technical transmission standards with the example given that the claims do not contain a diagnosis code. The role of pharmacist administered overrides at the point of sale as well as the physician prior authorization process was discussed. The Board indicated that additional reporting over longer periods of time should be analyzed and reviewed in DUR Committee with presentation back to the Board at a later date.

Schedule for 2017 meetings

The DUR Board decided on the meeting schedule for the remainder of 2017 and will meet on May 16th, September 26th and November 14th, 2017.

Adjournment

Dr. Presutti adjourned the meeting at 1:10 PM